Objective:

To emphasize the importance of establishing a dose ceiling in clinical trials evaluating early multimodal vasopressor therapy.

Approach:

• Analysis of TRICYCLE trial: Critique of the TRICYCLE trial's methodology regarding the use of norepinephrine equivalent (NEE) dose thresholds.
• Comparison with other trials: Comparison of baseline NEE and outcomes with other trials such as ATHOS-3 and VASST.
• Discussion on timing and dosing: Examination of the impact of timing and dosing on treatment outcomes in septic shock.

Key Findings:

• TRICYCLE trial set a NEE dose floor of ≥0.15 µg/kg/min but no ceiling, leading to higher baseline doses than intended.
• Patients in TRICYCLE were in a more severe state than those in previous studies, which may affect the interpretation of results.
• Timing of vasopressor initiation significantly impacts mortality outcomes, with earlier treatment associated with better survival rates.
• Renin levels were significantly higher in the intervention group, indicating a derangement of the renin-angiotensin system at baseline.

Interpretation:

The evaluated strategy in the TRICYCLE trial does not align with its intended design.

Limitations:

• The trial did not establish a ceiling for the qualifying dose of vasopressors.
• The interval between reaching the pressor threshold and randomization was not constrained.
• Lack of documentation on the timing of initiation for each vasopressor agent.

Conclusion:

Future studies on early multimodal vasopressor therapy should prioritize defining a ceiling dose and documenting treatment initiation timing.

Sources:

• TRICYCLE trial
• ATHOS-3 trial
• VASST trial